{
  "docId": "019de076-aef8-73ee-832d-fdb26bc98608",
  "docSlug": "c95c061ca7ee3d0fc69daa81d5a345ff",
  "documentTitle": "Legend Biotech | Investor Presentation Deck | 14 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 14,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "other",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide details three distinct manufacturing initiatives: the Obelisc facility in Ghent, J&J in-house Lentivirus production, and a CMO partnership with Novartis.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de076-aef8-73ee-832d-fdb26bc98608/11",
  "deckHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608",
  "deckJsonHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608.json",
  "deckAnchorHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "*All the Lentivirus facilities are owned by J&J.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c01fdd9-5b85-473c-9085-e8e9a78dd5c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.25,
        "x": 0.6,
        "y": 0.28
      },
      "kind": "image",
      "text": "Obelisc Facility",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48276504-0ee0-4e64-b90d-48ae1447f27f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "list",
      "text": "J&J In-House Lentivirus Facilities*: J&J facility in Switzerland now producing Lentivirus in-house... All commercial Lentivirus now produced in-house... Additional Lentivirus supply expected in 2024 and 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "418bf144-835e-4ceb-9478-5db1dd20441b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.54,
        "y": 0.6
      },
      "kind": "list",
      "text": "Novartis as CMO for Clinical Supply: Signed CMO agreement with Novartis during Q2 2023... On track to produce clinical materials in 1H 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1ea5e0d-8d7f-4fa9-a577-ad9e66381ecd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "list",
      "text": "State-Of-The-Art CARVYKTI® Manufacturing Facilities: Obelisc Facility in Ghent, Belgium received license... Awaiting Investigational Medicinal Product Dossier approvals... Anticipate manufacturing cilta-cel at Ghent for clinical use in January 2024 and commercial use in 2H 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9efcb7b-7011-4ea2-8fcb-5eb03bfb0bec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "subtitle",
      "text": "Bringing cell therapies to market given unique challenges to improve overall supply",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c437a821-f5e0-42cf-8d13-ccc4945b5bf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Expanding Our Manufacturing Capabilities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff3a3e33-8ade-4f11-8ab4-12c8f53c0e0f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "0058ca42-40b0-4ba0-b972-3082bdebeb48",
      "evidence": "list/bullet: State-Of-The-Art CARVYKTI® Manufacturing Facilities, list/bullet: J&J In-House Lentivirus Facilities",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}